These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22975341)

  • 1. A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.
    Wang D; Lao WF; Kuang YY; Geng SM; Mo LJ; He C
    Exp Cell Res; 2012 Dec; 318(20):2548-58. PubMed ID: 22975341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells.
    Ling Y; Kuang Y; Chen LL; Lao WF; Zhu YR; Wang LQ; Wang D
    Oncotarget; 2017 Jun; 8(24):39101-39116. PubMed ID: 28388571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells.
    Wang MH; Kurtz AL; Chen Y
    Carcinogenesis; 2000 Aug; 21(8):1507-12. PubMed ID: 10910951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
    Wang MH; Lao WF; Wang D; Luo YL; Yao HP
    Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
    Zhou YQ; He C; Chen YQ; Wang D; Wang MH
    Oncogene; 2003 Jan; 22(2):186-97. PubMed ID: 12527888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines.
    Chen YQ; Zhou YQ; Angeloni D; Kurtz AL; Qiang XZ; Wang MH
    Exp Cell Res; 2000 Nov; 261(1):229-38. PubMed ID: 11082293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.
    Collesi C; Santoro MM; Gaudino G; Comoglio PM
    Mol Cell Biol; 1996 Oct; 16(10):5518-26. PubMed ID: 8816464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
    Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
    Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.
    Zhang K; Zhou YQ; Yao HP; Wang MH
    Int J Oncol; 2010 Jan; 36(1):255-64. PubMed ID: 19956854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
    Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
    Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
    Lu Y; Yao HP; Wang MH
    Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
    Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
    Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant.
    Eckerich C; Schulte A; Martens T; Zapf S; Westphal M; Lamszus K
    J Neurochem; 2009 May; 109(4):969-80. PubMed ID: 19519771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
    Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
    Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
    Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
    Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression.
    Bardella C; Costa B; Maggiora P; Patane' S; Olivero M; Ranzani GN; De Bortoli M; Comoglio PM; Di Renzo MF
    Cancer Res; 2004 Aug; 64(15):5154-61. PubMed ID: 15289319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
    Krishnaswamy S; Mohammed AK; Tripathi G; Alokail MS; Al-Daghri NM
    BMC Cancer; 2017 Nov; 17(1):738. PubMed ID: 29121914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
    Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
    Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.
    Lu Y; Yao HP; Wang MH
    J Exp Clin Cancer Res; 2008 Oct; 27(1):55. PubMed ID: 18950514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
    Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
    Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.